{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T22:49:48Z","timestamp":1776898188950,"version":"3.51.2"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene Reports"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.genrep.2022.101619","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T12:24:59Z","timestamp":1651667099000},"page":"101619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Therapeutic approaches and vaccination in fighting COVID-19 infections: A review"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7519-7026","authenticated-orcid":false,"given":"Setare","family":"Adibzadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahin","family":"Amiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0801-8515","authenticated-orcid":false,"given":"Giti Esmail","family":"Nia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5582-8276","authenticated-orcid":false,"given":"Maryam Rezakhani","family":"Taleghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7720-5088","authenticated-orcid":false,"given":"Zahra Kohanrooz","family":"Bijarpas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7303-8742","authenticated-orcid":false,"given":"Neda","family":"Maserat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0699-3010","authenticated-orcid":false,"given":"Amirhosein","family":"Maali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5818-213X","authenticated-orcid":false,"given":"Mehdi","family":"Azad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5917-920X","authenticated-orcid":false,"given":"Abbas","family":"Behzad-Behbahani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.genrep.2022.101619_bb0005","series-title":"Emergency Use Authorization 100 [Online]. Available: Emergency Use Authorization","volume":"100","author":"Administration","year":"2021"},{"key":"10.1016\/j.genrep.2022.101619_bb0010","author":"Administration"},{"key":"10.1016\/j.genrep.2022.101619_bb0015","author":"Administration"},{"key":"10.1016\/j.genrep.2022.101619_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179124","article-title":"Exploring the binding mechanism of PF-07321332 SARS-CoV-2 protease inhibitor through molecular dynamics and binding free energy simulations","volume":"22","author":"Ahmad","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.genrep.2022.101619_bb0025","series-title":"A Five-day Course of Ivermectin for the Treatment of COVID-19 May Reduce the Duration of Illness","first-page":"214","volume":"103","author":"Ahmed","year":"2021"},{"key":"10.1016\/j.genrep.2022.101619_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.659577","article-title":"Therapeutic effectiveness and safety of repurposing drugs for the treatment of COVID-19: position standing in 2021","volume":"12","author":"Alam","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.genrep.2022.101619_bb0035","first-page":"1","article-title":"COVID-19: a novel coronavirus and a novel challenge for critical care","author":"Arabi","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.genrep.2022.101619_bb0040","author":"Arena"},{"issue":"3","key":"10.1016\/j.genrep.2022.101619_bb1000","first-page":"311","article-title":"Common polymorphism\u2019s analysis of thiopurine S-methyltransferase (TPMT) in Iranian population","volume":"11","author":"Azad","year":"2009","journal-title":"Cell J."},{"key":"10.1016\/j.genrep.2022.101619_bb0045","series-title":"Alpha 1 Antitrypsin Is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2","author":"Azouz","year":"2020"},{"key":"10.1016\/j.genrep.2022.101619_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173922","article-title":"SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: an in silico drug repurposing study","volume":"896","author":"Baby","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.genrep.2022.101619_bb0055","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/BF01649442","article-title":"Alpha-lipoic acid is an effective inhibitor of human immuno-deficiency virus (HIV-1) replication","volume":"69","author":"Baur","year":"1991","journal-title":"Klin. Wochenschr."},{"key":"10.1016\/j.genrep.2022.101619_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacbts.2020.10.003","article-title":"The integrin binding peptide, ATN-161, as a novel therapy for SARS-CoV-2 infection","volume":"6","author":"Beddingfield","year":"2021","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.genrep.2022.101619_bb0065","series-title":"TMPRSS2 and Furin Are Both Essential for Proteolytic Activation of SARS-CoV-2 in Human Airway Cells","volume":"3","author":"Bestle","year":"2020"},{"key":"10.1016\/j.genrep.2022.101619_bb0070","author":"Biocentury"},{"key":"10.1016\/j.genrep.2022.101619_bb0075","author":"Biotech"},{"key":"10.1016\/j.genrep.2022.101619_bb0080","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/1040841X.2020.1739001","article-title":"Emergence of novel coronavirus and COVID-19: whether to stay or die out?","volume":"46","author":"Biswas","year":"2020","journal-title":"Crit. Rev. Microbiol."},{"key":"10.1016\/j.genrep.2022.101619_bb0085","article-title":"Adjunct immunotherapies for the management of severely ill COVID-19 patients","volume":"1","author":"Bonam","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.genrep.2022.101619_bb0090","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/092986708784049658","article-title":"Arbidol: a broad-spectrum antiviral compound that blocks viral fusion","volume":"15","author":"Boriskin","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.genrep.2022.101619_bb0095","author":"Businesswire"},{"key":"10.1016\/j.genrep.2022.101619_bb0100","article-title":"Interferon therapy for COVID-19 and emerging infections: prospects and concerns","volume":"87","author":"Calabrese","year":"2020","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.genrep.2022.101619_bb0105","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.genrep.2022.101619_bb0110","series-title":"De Novo Design of Picomolar SARS-CoV-2 Miniprotein Inhibitors","first-page":"426","volume":"370","author":"Cao","year":"2020"},{"key":"10.1016\/j.genrep.2022.101619_bb0115","author":"CDC"},{"key":"10.1016\/j.genrep.2022.101619_bb0120","author":"CEPI"},{"key":"10.1016\/j.genrep.2022.101619_bb0125","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023357","article-title":"First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.genrep.2022.101619_bb0130","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.genrep.2022.101619_bb0135","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.genrep.2022.101619_bb0140","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41423-020-0426-7","article-title":"Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor","volume":"17","author":"Chen","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.genrep.2022.101619_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108254","article-title":"Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects","volume":"33","author":"Cheng","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.genrep.2022.101619_bb0150","author":"CHICTR"},{"key":"10.1016\/j.genrep.2022.101619_bb0155","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.genrep.2022.101619_bb0160","author":"ClinicalTrials"},{"key":"10.1016\/j.genrep.2022.101619_bb0165","author":"ClinicalTrials"},{"key":"10.1016\/j.genrep.2022.101619_bb0170","author":"ClinicalTrials"},{"key":"10.1016\/j.genrep.2022.101619_bb0175","author":"ClinicalTrials"},{"key":"10.1016\/j.genrep.2022.101619_bb0180","author":"ClinicalTrials"},{"key":"10.1016\/j.genrep.2022.101619_bb0185","author":"ClinicalTrials"},{"key":"10.1016\/j.genrep.2022.101619_bb0190","author":"ClinicalTrials"},{"key":"10.1016\/j.genrep.2022.101619_bb0195","author":"ClinicalTrials"},{"key":"10.1016\/j.genrep.2022.101619_bb0200","author":"ClinicalTrials"},{"key":"10.1016\/j.genrep.2022.101619_bb0205","author":"ClinicalTrials"},{"key":"10.1016\/j.genrep.2022.101619_bb0210","author":"ClinicalTrials"},{"key":"10.1016\/j.genrep.2022.101619_bb0215","author":"ClinicalTrials"},{"key":"10.1016\/j.genrep.2022.101619_bb0220","author":"ClinicalTrials"},{"key":"10.1016\/j.genrep.2022.101619_bb0225","author":"ClinicalTrials"},{"key":"10.1016\/j.genrep.2022.101619_bb0230","author":"ClinicalTrials"},{"key":"10.1016\/j.genrep.2022.101619_bb0235","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","volume":"57","author":"Cortegiani","year":"2020","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.genrep.2022.101619_bb0240","series-title":"Coronavirus Drug and Treatment Tracker","author":"Corum","year":"2020"},{"key":"10.1016\/j.genrep.2022.101619_bb0245","author":"CTRI"},{"key":"10.1016\/j.genrep.2022.101619_bb0250","first-page":"ii5-ii10","article-title":"Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations","volume":"65 Suppl 2","author":"Davies","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.genrep.2022.101619_bb0255","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01061-20","article-title":"A randomized clinical trial of the efficacy and safety of interferon beta-1a in treatment of severe COVID-19","volume":"64","author":"Davoudi-Monfared","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.genrep.2022.101619_bb0260","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.genrep.2022.101619_bb0265","article-title":"Therapeutic potential of alpha-lipoic acid in viral infections, including COVID-19","volume":"10","author":"Dragomanova","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.genrep.2022.101619_bb0270","author":"DrugBank"},{"key":"10.1016\/j.genrep.2022.101619_bb0275","author":"Edudwar"},{"key":"10.1016\/j.genrep.2022.101619_bb0280","author":"Exterior"},{"key":"10.1016\/j.genrep.2022.101619_bb0285","author":"Fastercures"},{"key":"10.1016\/j.genrep.2022.101619_bb0290","author":"FDA"},{"key":"10.1016\/j.genrep.2022.101619_bb0295","series-title":"Peginterferon-lambda for the Treatment of COVID-19 in Outpatients","author":"Feld","year":"2020"},{"key":"10.1016\/j.genrep.2022.101619_bb0300","author":"Finlay"},{"key":"10.1016\/j.genrep.2022.101619_bb0305","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/v13030418","article-title":"Target product profile analysis of COVID-19 vaccines in phase III clinical trials and beyond: an early 2021 perspective","volume":"13","author":"Funk","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.genrep.2022.101619_bb0310","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.genrep.2022.101619_bb0315","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1056\/NEJMp2003762","article-title":"Responding to Covid-19 - a once-in-a-century pandemic?","volume":"382","author":"Gates","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.genrep.2022.101619_bb0320","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.genrep.2022.101619_bb0325","series-title":"Severe Acute Respiratory Syndrome-related Coronavirus\u2013The Species and Its Viruses, a Statement of the Coronavirus Study Group","author":"Gorbalenya","year":"2020"},{"key":"10.1016\/j.genrep.2022.101619_bb0330","doi-asserted-by":"crossref","first-page":"8853056","DOI":"10.1155\/2021\/8853056","article-title":"An updated review of computer-aided drug design and its application to COVID-19","volume":"2021","author":"Gurung","year":"2021","journal-title":"Biomed. Res. Int."},{"issue":"271\u2013280","key":"10.1016\/j.genrep.2022.101619_bb0335","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.genrep.2022.101619_bb0340","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.genrep.2022.101619_bb0345","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S2213-2600(21)00402-1","article-title":"Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan","volume":"9","author":"Hsieh","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.genrep.2022.101619_bb0355","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.genrep.2022.101619_bb0360","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3389\/fphar.2020.01169","article-title":"Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention","volume":"11","author":"Hussman","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.genrep.2022.101619_bb0365","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3389\/fphar.2021.632677","article-title":"An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?","volume":"12","author":"Indari","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.genrep.2022.101619_bb0370","author":"Iran-Press"},{"key":"10.1016\/j.genrep.2022.101619_bb0375","author":"IRCT"},{"key":"10.1016\/j.genrep.2022.101619_bb0380","author":"IRCT"},{"key":"10.1016\/j.genrep.2022.101619_bb0385","author":"IRCT"},{"key":"10.1016\/j.genrep.2022.101619_bb0390","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4062\/biomolther.2019.202","article-title":"Small molecule inhibitors of Middle East respiratory syndrome coronavirus fusion by targeting cavities on heptad repeat trimers","volume":"28","author":"Kandeel","year":"2020","journal-title":"Biomol. Ther. (Seoul)"},{"key":"10.1016\/j.genrep.2022.101619_bb0395","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4062\/biomolther.2020.201","article-title":"Discovery of new fusion inhibitor peptides against SARS-CoV-2 by targeting the spike S2 subunit","volume":"29","author":"Kandeel","year":"2021","journal-title":"Biomol. Ther. (Seoul)"},{"key":"10.1016\/j.genrep.2022.101619_bb0400","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phclin.2020.06.003","article-title":"COVID-19 and Therapeutic Drugs Repurposing in Hand: The Need for Collaborative Efforts","volume":"56","author":"Khan","year":"2021","journal-title":"Le Pharmacien Hospitalier et Clinicien"},{"key":"10.1016\/j.genrep.2022.101619_bb0405","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.2020.22813","article-title":"Therapy for early COVID-19: a critical need","volume":"324","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.genrep.2022.101619_bb0410","doi-asserted-by":"crossref","first-page":"7","DOI":"10.29121\/granthaalayah.v8.i4.2020.2","article-title":"Favipiravir as a potential drug in the treatment of COVID-19","volume":"8","author":"Kramer","year":"2020","journal-title":"Int. J. Res. Granthaalayah"},{"key":"10.1016\/j.genrep.2022.101619_bb0415","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.genrep.2022.101619_bb0420","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/s41467-020-16048-4","article-title":"Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-ig","volume":"11","author":"Lei","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.genrep.2022.101619_bb0425","article-title":"Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of Lopinavir\/Ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.genrep.2022.101619_bb0430","series-title":"Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases","author":"Liu","year":"2020"},{"key":"10.1016\/j.genrep.2022.101619_bb0435","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","article-title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)","volume":"14","author":"Lu","year":"2020","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.genrep.2022.101619_bb0440","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4269\/ajtmh.20-0375","article-title":"Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis","volume":"103","author":"Luo","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.genrep.2022.101619_bb0445","article-title":"Pharmacologic perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19","volume":"105995","author":"Luoliu","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.genrep.2022.101619_bb0450","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.3390\/ijms21197189","article-title":"Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19","volume":"21","author":"McGowan","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.genrep.2022.101619_bb0455","series-title":"Efficacy and Safety of SOBERANA 02, a COVID-19 Conjugate Vaccine in Heterologous Three Doses Combination","author":"Medrxiv","year":"2021"},{"key":"10.1016\/j.genrep.2022.101619_bb0460","article-title":"Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19","volume":"5","author":"Mohamed","year":"2020"},{"key":"10.1016\/j.genrep.2022.101619_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107763","article-title":"An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages","volume":"96","author":"Motamedi","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.genrep.2022.101619_bb0470","author":"MPNRC"},{"key":"10.1016\/j.genrep.2022.101619_bb0480","author":"Nature"},{"key":"10.1016\/j.genrep.2022.101619_bb0485","author":"Nature"},{"key":"10.1016\/j.genrep.2022.101619_bb0490","series-title":"Multidrug Treatment With Nelfinavir and Cepharanthine Against COVID-19","author":"Ohashi","year":"2020"},{"key":"10.1016\/j.genrep.2022.101619_bb0495","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2165\/00003495-200666090-00012","article-title":"Lopinavir\/ritonavir: a review of its use in the management of HIV infection","volume":"66","author":"Oldfield","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.genrep.2022.101619_bb0500","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.genrep.2022.101619_bb0505","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01935-20","article-title":"Inhibition of coronavirus entry in vitro and ex vivo by a lipid-conjugated peptide derived from the SARS-CoV-2 spike glycoprotein HRC domain","volume":"11","author":"Outlaw","year":"2020","journal-title":"MBio"},{"key":"10.1016\/j.genrep.2022.101619_bb0510","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02428-20","article-title":"Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.genrep.2022.101619_bb0515","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.addr.2020.12.008","article-title":"Non-viral COVID-19 vaccine delivery systems","volume":"169","author":"Park","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.genrep.2022.101619_bb0520","first-page":"399","article-title":"Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: a multicentre retrospective matched cohort study","volume":"9","author":"Que","year":"2003","journal-title":"Hong Kong Med. J."},{"key":"10.1016\/j.genrep.2022.101619_bb0525","series-title":"Potential Small-molecule Drugs as Available Weapons to Fight Novel Coronavirus (2019-nCoV): A review","first-page":"4","volume":"39","author":"Rahimkhoei","year":"2021"},{"key":"10.1016\/j.genrep.2022.101619_bb0530","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0250147","article-title":"Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta","volume":"16","author":"Ramatillah","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.genrep.2022.101619_bb0535","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2007.05.015","article-title":"Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century","volume":"30","author":"Rolain","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.genrep.2022.101619_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","volume":"109","author":"Rothan","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.genrep.2022.101619_bb0545","author":"RPCEC"},{"key":"10.1016\/j.genrep.2022.101619_bb0550","author":"RPCEC"},{"key":"10.1016\/j.genrep.2022.101619_bb0555","author":"Russian-News-Agency"},{"key":"10.1016\/j.genrep.2022.101619_bb0560","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.genrep.2022.101619_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108183","article-title":"Metformin in COVID-19: a possible role beyond diabetes","volume":"164","author":"Sharma","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.genrep.2022.101619_bb0570","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.1016\/S2214-109X(21)00043-7","article-title":"An interactive website tracking COVID-19 vaccine development","volume":"9","author":"Shrotri","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.genrep.2022.101619_bb0575","article-title":"Drug treatments for covid-19: living systematic review and network meta-analysis","volume":"370","author":"Siemieniuk","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.genrep.2022.101619_bb0580","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.3389\/fmicb.2017.02677","article-title":"Advances in diagnosis, surveillance, and monitoring of Zika virus: an update","volume":"8","author":"Singh","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.genrep.2022.101619_bb0585","author":"Tehran-Times"},{"key":"10.1016\/j.genrep.2022.101619_bb0590","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.micinf.2019.02.002","article-title":"Advances in diagnostics, vaccines and therapeutics for Nipah virus","volume":"21","author":"Thakur","year":"2019","journal-title":"Microbes Infect."},{"key":"10.1016\/j.genrep.2022.101619_bb0595","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Thanh","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.genrep.2022.101619_bb0600","author":"Today"},{"key":"10.1016\/j.genrep.2022.101619_bb0605","author":"Tracker"},{"key":"10.1016\/j.genrep.2022.101619_bb0610","author":"Translation"},{"key":"10.1016\/j.genrep.2022.101619_bb0615","author":"Vejthani-Hospital"},{"key":"10.1016\/j.genrep.2022.101619_bb0620","series-title":"Covid-19: A Puzzle With Many Missing Pieces","author":"Vetter","year":"2020"},{"key":"10.1016\/j.genrep.2022.101619_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2020.111805","article-title":"Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic","volume":"146","author":"Vlachakis","year":"2020","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.genrep.2022.101619_bb0630","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.genrep.2022.101619_bb0635","series-title":"Peptide Antidotes to SARS-CoV-2 (COVID-19). 2020.08.06.238915","author":"Watson","year":"2020"},{"key":"10.1016\/j.genrep.2022.101619_bb0640","author":"WEGO"},{"key":"10.1016\/j.genrep.2022.101619_bb0645","author":"Worldometers"},{"key":"10.1016\/j.genrep.2022.101619_bb0650","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","article-title":"Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment","volume":"397","author":"Wouters","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.genrep.2022.101619_bb0655","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.genrep.2022.101619_bb0660","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","article-title":"Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein","volume":"17","author":"Xia","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.genrep.2022.101619_bb0665","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jinf.2020.03.044","article-title":"Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19","volume":"81","author":"Xie","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.genrep.2022.101619_bb0670","doi-asserted-by":"crossref","first-page":"101078","DOI":"10.1016\/j.eclinm.2021.101078","volume":"39","author":"Zakarya","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.genrep.2022.101619_bb0675","first-page":"1","article-title":"Analysis of Epidemiological characteristics of new coronavirus pneumonia","volume":"41","author":"Zhang","year":"2020","journal-title":"Chin. J. Epidemiol."},{"key":"10.1016\/j.genrep.2022.101619_bb0680","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jmv.25707","article-title":"Potential interventions for novel coronavirus in China: a systemic review","volume":"92","author":"Zhang","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.genrep.2022.101619_bb0685","series-title":"Teicoplanin Potently Blocks the Cell Entry of 2019-nCoV. 2020.02.05.935387","author":"Zhang","year":"2020"},{"key":"10.1016\/j.genrep.2022.101619_bb0690","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1038\/s41467-020-17986-9","article-title":"A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2","volume":"11","author":"Zhao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.genrep.2022.101619_bb0695","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","volume":"81","author":"Zhu","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.genrep.2022.101619_bb0700","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1148\/radiol.2020200490","article-title":"Coronavirus disease 2019 (COVID-19): a perspective from China","volume":"296","author":"Zu","year":"2020","journal-title":"Radiology"}],"container-title":["Gene Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452014422001273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452014422001273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:17:31Z","timestamp":1762528651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452014422001273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":139,"alternative-id":["S2452014422001273"],"URL":"https:\/\/doi.org\/10.1016\/j.genrep.2022.101619","relation":{},"ISSN":["2452-0144"],"issn-type":[{"value":"2452-0144","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic approaches and vaccination in fighting COVID-19 infections: A review","name":"articletitle","label":"Article Title"},{"value":"Gene Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genrep.2022.101619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101619"}}